Cargando…

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation

The use of antibody induction after kidney transplantation has increased from 25% to 63% in the past decade and roughly one half of the induction agent used is anti-interleukin-2 receptor antibody (IL-2RA, ie, basiliximab or daclizumab). When combined with calcineurin inhibitor (CNI)-based immunosup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sageshima, Junichiro, Ciancio, Gaetano, Chen, Linda, Burke, George W
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726067/ https://www.ncbi.nlm.nih.gov/pubmed/19707418

Ejemplares similares

Efficacy of Anti-Interleukin-2 Receptor Antibody (Daclizumab) in Reducing the Incidence of Acute Rejection After Renal Transplantation
por: Saghafi, Hossein, et al.
Publicado: (2012)

Aneurysmectomy with Partial Nephrectomy on a Living Donor Renal Allograft: A Case Report
por: Paloyo, Siegfredo, et al.
Publicado: (2013)

The role of basiliximab in the evolving renal transplantation immunosuppression protocol
por: Salis, Paola, et al.
Publicado: (2008)

Role of basiliximab in the prevention of acute cellular rejection in adult to adult living-related liver transplantation: a single center experience
por: Gruttadauria, S, et al.
Publicado: (2007)

Efficacy of basiliximab induction in poorly matched living donor renal transplantation
por: Gundlapalli, S., et al.
Publicado: (2013)

Basiliximab for the therapy of acute T cell–mediated rejection in kidney transplant recipient with BK virus infection: A case report
por: Chen, Tingting, et al.
Publicado: (2022)

Efficacy of Anti-Interleukin-2 Receptor Antibody in Reducing the Incidence of Acute Rejection After Renal Transplantation
por: Liborio, Alexandre Braga, et al.
Publicado: (2012)

The Effect of Monthly Anti-CD25(+) Treatment with Basiliximab on the Progression of Chronic Renal Dysfunction after Lung Transplantation
por: Ross, D. J., et al.
Publicado: (2020)

A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
por: Mullen, John C, et al.
Publicado: (2014)

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

Comparison of Basiliximab and Anti‐Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis
por: Ansari, David, et al.
Publicado: (2015)

Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
por: Masset, Christophe, et al.
Publicado: (2023)

Prospective Controlled Protocol for Three Months Steroid Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients
por: Oh, Chang-Kwon, et al.
Publicado: (2012)

Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates
por: Kim, Ha Eun, et al.
Publicado: (2021)

A Randomized Prospective Study Comparing Anti–T-Lymphocyte Igs to Basiliximab in Highly Sensitized Kidney Transplant Patients
por: Kamar, Nassim, et al.
Publicado: (2020)

Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
por: Furukawa, Masashi, et al.
Publicado: (2022)

Basiliximab for early perioperative transplant-associated thrombotic microangiopathy after lung transplantation: a case report
por: Ijiri, Naohiro, et al.
Publicado: (2022)

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
por: Karunaratne, Kushan, et al.
Publicado: (2021)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
por: Kim, Sang Jin, et al.
Publicado: (2020)

Anti‐interleukin‐6 antibody clazakizumab in late antibody‐mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism
por: Mühlbacher, Jakob, et al.
Publicado: (2021)

Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
por: Jeong, Rachel, et al.
Publicado: (2020)

Thymoglobulin Versus Alemtuzumab Versus Basiliximab Kidney Transplantation From Donors After Circulatory Death
por: Asderakis, Argiris, et al.
Publicado: (2022)

Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study
por: Widman, Guido, et al.
Publicado: (2015)

Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
Publicado: (2021)

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
por: Koch, Martina, et al.
Publicado: (2009)

Chronic Renal Transplant Rejection and Possible Anti-Proliferative Drug Targets
por: Bhatti, Adnan Bashir, et al.
Publicado: (2015)

Preventing Rejection of the Kidney Transplant
por: Malhotra, Divyanshu, et al.
Publicado: (2023)

Recent advances in renal transplantation: antibody-mediated rejection takes center stage
por: Pouliquen, Eric, et al.
Publicado: (2015)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study
por: Lam, Ngan N., et al.
Publicado: (2021)

The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
por: Hong, Su Yeon, et al.
Publicado: (2023)

Feasibility of renal transplantation after unroofing of a large renal cyst in an expanded criteria donor
por: Kanagarajah, Prashanth, et al.
Publicado: (2013)

Rabbit anti‐thymocyte globulin for the prevention of acute rejection in kidney transplantation
por: Alloway, Rita R., et al.
Publicado: (2019)

Impact of Induction Immunosuppressants on T Lymphocyte Subsets after Kidney Transplantation: A Prospective Observational Study with Focus on Anti-Thymocyte Globulin and Basiliximab Induction Therapies
por: Kim, Hyung Duk, et al.
Publicado: (2023)

Challenges inherent to the diagnosis of antibody-mediated rejection in lung transplantation
por: Chin, Nicholas, et al.
Publicado: (2015)

Association between anti‐endothelial antigen antibodies and allograft rejection in kidney transplantation
por: Lee, Hyun Ji, et al.
Publicado: (2023)

Anti-complement 5 antibody ameliorates antibody-mediated rejection after liver transplantation in rats
por: Tajima, Tetsuya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ovm0k576ul1llgesrpdkpa13ed